FY2025 EPS Estimates for UTHR Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) estimate for United Therapeutics from $28.43 to $28.70, suggesting a positive outlook for the biotechnology company.
• Despite a recent quarterly earnings miss of $6.41 EPS against an expectation of $6.80, United Therapeutics saw an 11.7% revenue growth year-over-year, reaching $798.60 million.
• The stock currently has a consensus rating of "Moderate Buy," with analysts setting price targets ranging from $330.00 to $575.00, indicating strong institutional interest and potential for growth.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for United Therapeutics in a research note issued on Wednesday, September 10th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will post earnings of $28.70 per share for the year, up from their previous estimate of $28.43. Cantor Fitzgerald has a "Overweight" rating and a $525.00 price objective on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the company earned $5.85 earnings per share. The firm's revenue was up 11.7% compared to the same quarter last year.

A number of other research analysts have also weighed in on UTHR. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research report on Thursday, September 4th. JPMorgan Chase & Co. reduced their target price on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. HC Wainwright increased their target price on United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Finally, Jefferies Financial Group boosted their price target on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $438.85.

United Therapeutics Stock Performance

Shares of UTHR opened at $404.84 on Friday. The stock has a 50 day simple moving average of $316.32 and a 200 day simple moving average of $307.23. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $436.95. The firm has a market capitalization of $18.26 billion, a PE ratio of 15.80, a P/E/G ratio of 6.05 and a beta of 0.62.

Insider Activity

In related news, Director Tommy G. Thompson sold 4,560 shares of the stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $403.36, for a total value of $1,839,321.60. Following the sale, the director owned 8,480 shares in the company, valued at approximately $3,420,492.80. This represents a 34.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jan Malcolm sold 700 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $400.29, for a total transaction of $280,203.00. Following the sale, the director owned 520 shares of the company's stock, valued at approximately $208,150.80. This represents a 57.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 128,816 shares of company stock valued at $45,836,113. 10.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the period. SVB Wealth LLC acquired a new stake in shares of United Therapeutics during the first quarter worth $32,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 85 shares during the period. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.